


ORIGINAL RESEARCH

Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion



Xiaojie Yu,^{1,2} Natalia Elfimova,¹ Marion Müller,^{1,2} Daniel Bachurski,³ Ulrike Koitzsch,^{1,2} Uta Drebber,^{1,4} Esther Mahabir,² Hinrich P. Hansen,^{3,4} Scott L. Friedman,⁵ Sabine Klein,⁶ Hans Peter Dienes,¹ Marianna Hösel,^{1,2} Reinhard Buettner,^{1,2,4} Jonel Trebicka,^{6,7} Vangelis Kondylis,^{1,2,8} Inge Mannaerts,⁹ and Margarete Odenthal^{1,2,4}

¹Institute for Pathology, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany; ²Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; ³Department I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany; ⁴Center of Integrative Oncology, University Clinic of Cologne and Bonn, Germany; ⁵Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; ⁶Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany; ⁷European Foundation for the Study of Chronic Liver Failure - EF CLIF, Barcelona, Spain; ⁸Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany; and ⁹Liver Cell Biology Research Group, Vrije Universiteit Brussel, Brussel, Belgium



SUMMARY

Cellular miR-29a, inhibiting collagen synthesis, is reduced in activated HSC because of its vesicular release upon autophagy induction by profibrogenic TGF β or PDGF-BB stimulation. Accordingly, autophagy in HSC of clinical specimens with liver fibrosis was linked to elevated serum miR-29a levels.

BACKGROUND & AIMS: Liver fibrosis arises from long-term chronic liver injury, accompanied by an accelerated wound healing response with interstitial accumulation of extracellular matrix (ECM). Activated hepatic stellate cells (HSC) are the

main source for ECM production. MicroRNA29a (miR-29a) is a crucial antifibrotic miRNA that is repressed during fibrosis, resulting in up-regulation of collagen synthesis.

METHODS: Intracellular and extracellular miRNA levels of primary and immortalized myofibroblastic HSC in response to profibrogenic stimulation by transforming growth factor β (TGF β) or platelet-derived growth factor-BB (PDGF-BB) or upon inhibition of vesicular transport and autophagy processes were determined by quantitative polymerase chain reaction. Autophagy flux was studied by electron microscopy, flow cytometry, immunoblotting, and immunocytochemistry. Hepatic and serum miR-29a levels were quantified by using both liver tissue and serum samples from a cohort of chronic hepatitis C virus patients and a murine CCl₄ induced liver fibrosis model.

RESULTS: In our study, we show that TGF β and PDGF-BB resulted in decrease of intracellular miR-29a and a pronounced increase of vesicular miR-29a release into the supernatant. Strikingly, miR-29a vesicular release was accompanied by enhanced autophagic activity and up-regulation of the autophagy marker protein LC3. Moreover, autophagy inhibition strongly prevented miR-29a secretion and repressed its targets' expression such as Col1A1. Consistently, hepatic miR-29a loss and increased LC3 expression in myofibroblastic HSC were associated with increased serum miR-29a levels in CCl₄-treated murine liver fibrosis and specimens of hepatitis C virus patients with chronic liver disease.

CONCLUSIONS: We provide evidence that activation-associated autophagy in HSC induces release of miR-29a, whereas inhibition of autophagy represses fibrogenic gene expression in part through attenuated miR-29a secretion. (*Cell Mol Gastroenterol Hepatol* 2022;13:1701–1716; <https://doi.org/10.1016/j.jcmgh.2022.02.013>)

Keywords: Circulating MiRNA; MiR-29; Liver Fibrosis.

Liver fibrosis represents a major cause of morbidity and mortality worldwide. It is the pathophysiological consequence of different types of chronic inflammatory liver diseases, including liver injury upon viral hepatitis, alcoholic or drug abuse, in response to metabolic syndrome and fat accumulation, or upon autoimmune or genetic disorders.¹ Transforming growth factor β (TGF β) is the central mediator that is responsible for the imbalance between extracellular matrix (ECM) synthesis and degradation in human and experimental liver fibrosis.^{2,3} TGF β signaling includes various pathways such as the non-canonical TAK1/JNK and the RAS/RAF/MAPK pathways as well as the canonical SMAD pathway, leading to induction of ECM synthesis.^{4,5} In response to liver injury, increased TGF β levels stimulate hepatic stellate cells (HSC) to transdifferentiate into myofibroblasts,^{6,7} which are then the main source of ECM production in the fibrotic liver. Among the ECM proteins of fibrotic liver, fibrillar collagens such as collagen I and III are highly increased.^{2,3,8}

TGF β -induced myofibroblastic HSC activation is not only associated with ECM synthesis but also with an enhanced expression of profibrogenic growth factors such as TGF β itself, connective tissue growth factor, and platelet-derived growth factor (PDGF).^{2,3} PDGF is a mitogenic growth factor whose polypeptide chains A and B are arranged in AA, AB, or in BB combinations. Autocrine PDGF-BB stimulation is most potent to induce HSC proliferation.^{9,10} Hence, the autocrine stimulation of HSC by the altered growth factor profile, in particular by TGF β and PDGF-BB, triggers HSC activation and maintenance of liver fibrogenesis.^{2,3,8} Furthermore, exposure of HSC to both mediators potently decreases miR-29.^{11,12} MicroRNAs (miRNAs) are small non-coding RNAs, which participate in regulation of gene expression by their interaction with transcripts and subsequent inhibition of mRNA translation. Because the interacting region of miRNAs, the so-called seed region, is only 7–8 base pairs long, one mRNA is often regulated by several miRNAs, and one miRNA can interact with more than one


mRNA transcript.^{13,14} The members of the miR-29 family are known to target transcripts that encode various ECM members (eg, elastin, fibrillin, and various collagen subunits). Therefore, miR-29 acts as an antifibrotic miRNA, which is markedly diminished during acute and chronic liver disease.^{12,15–20}

In the present study, we show that TGF β - and PDGF-BB-mediated miR-29 decrease in HSC is associated with autophagy-related vesicular release. Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved cellular mechanism, which recycles the cytoplasm components, generates energy under stress conditions, removes superfluous and damaged organelles, adapts to changing nutrient conditions, and maintains cellular homeostasis. Autophagy involves the coordination of numerous autophagy-related (ATG) proteins and the formation of double membrane autophagosomes.

Recent studies have linked liver damage and fibrogenesis to autophagy, affecting hepatic cell types in a different manner.^{21,22} Whereas in macrophages and endothelial cells inhibition of autophagy accelerates fibrogenesis, in hepatocytes autophagy is important for cellular homeostasis and inhibition leads to development of liver tumors.^{23,24} In HSC, autophagy promotes the activation and transdifferentiation processes into myofibroblasts, associated with increased ECM synthesis and the enhanced catabolism of fatty acids, providing then the necessary energy for cell activation.²⁵ Hence, the blockade of autophagy during liver fibrogenesis by HSC-specific ATG7 deletion maintains resistance to its activation and liver fibrosis.²⁶ TGF β stimulates autophagy and is a central driver of autophagy in fibroblasts and in HSC.^{27,28} Interestingly, not only TGF β but also PDGF-BB stimulates autophagy in HSC,²⁵ and inhibition of autophagy represses collagen synthesis.²⁹

In this study, we demonstrate that autophagy, induced by TGF β and PDGF-BB, directly regulates cellular miR-29a levels in myofibroblastic HSC. Notably, autophagy lowers cellular miR-29a levels by inducing its release into secreted extracellular vesicles (EV), thereby attenuating intracellular antifibrotic functions of miR-29a, including inhibition of collagen I synthesis. Moreover, autophagy-induced miR-29a increases circulating miR-29 levels in serum samples of patients with hepatitis C virus (HCV)-associated fibrosis. Increased extracellular miR-29a levels are significantly correlated with fibrosis progression of patients with chronic HCV liver disease.

Abbreviations used in this paper: α SMA, alpha smooth muscle actin; ATG, autophagy-related; DMEM, Dulbecco modified Eagle medium; ECM, extracellular matrix; EV, extracellular vesicles; FCS, fetal calf serum; HCV, hepatitis C virus; HSC, hepatic stellate cells; miRNA, microRNA; mTOR, mammalian target of rapamycin; PCR, polymerase chain reaction; PDGF, platelet-derived growth factor; siRNA, small interfering RNA; TGF β , transforming growth factor beta; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

 Most current article

© 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2352-345X

<https://doi.org/10.1016/j.jcmgh.2022.02.013>

Results

TGF β and PDGF-BB Stimulation Results in Vesicular Release From HSC

Because isolated primary HSC in culture spontaneously transdifferentiate into myofibroblasts, we first studied the miR-29a levels in primary mouse HSC after taking them into culture. Whereas in freshly isolated HSC miR-29a was highly abundant, miR-29a levels were decreased during culture and much lower in HSC, which were maintained in culture for 7 days and expressed the myofibroblast-specific marker α -smooth muscle actin (α SMA) (Figure 1A). Previous studies have shown that TGF β and PDGF-BB are main stimulators of myofibroblastic transition. In addition, they lead to miR-29 decrease and to enhanced ECM deposition.^{15,30,31} After profibrogenic stimulation with TGF β or PDGF-BB treatment, cellular miR-29a was reduced in immortalized myofibroblastic HSC by more than 70% as shown in Figure 1B and C (left panel). Surprisingly, analysis of the supernatants of TGF β and PDGF-BB stimulated HSC revealed that the supernatants from stimulated HSC contained significantly more extracellular miR-29a than the corresponding controls (Figure 1B and C, middle panel). Cellular release of miRNA can be caused by cell apoptosis/necrosis followed by generation of apoptotic bodies, but also by actively regulated vesicular release.³² To rule out the possibility that miR-29 release is due to cell death, we controlled the extent of apoptosis and necrosis. Deoxyuride-5'-triphosphate biotin nick end labeling (TUNEL) assays (Figure 1D) and annexin V cytometry (Figure 1E) clearly showed that there was no increase of apoptosis or necrosis, indicating that miR-29a release upon fibrogenic stimulation is a cell-regulated mechanism.

In an attempt to investigate the mechanism underlying miR-29 release in response to TGF β and PDGF-BB, vesicles from HSC culture supernatants were purified to quantify the extracellular miR-29 content. Indeed, TGF β and PDGF-BB stimulation significantly increased the levels of vesicular miR-29a (Figure 1B and C, right panel). By immunoblotting we showed that vesicles were CD63 and TSG101 positive (Figure 1F). Moreover, the increase of extracellular miR-29 in the cell culture supernatant was accompanied by marked elevation of its vesicular fraction (Figure 1G). The vesicle fraction was imaged by electron microscope (Figure 1H) and nanoparticle tracking analysis (Figure I), establishing that their size was 100–200 nm in diameter, which corresponds to the size of small EV.³³

Inhibition of Vesicle Transport Leads to Increment of Cellular miR-29a in Response to Profibrogenic Stimulation

Because miR-29a was enclosed in vesicles and secreted into the supernatant upon profibrogenic stimulation, we next investigated which cellular mechanism triggers miR-29a transport into the extracellular environment. It has been previously reported that vesicles require myosin motor proteins.³⁴ Blebbistatin, a myosin II ATPase inhibitor, is a potent inhibitor of both cell contraction and vesicular

transport.³⁵ Inhibition of vesicle transport by blebbistatin significantly inhibited TGF β -induced miR-29a secretion, as evidenced by an increase in cellular miR-29a (Figure 2A, left) on the one hand and a significant decrease in extracellular miR-29a in HSC culture supernatants on the other (Figure 2A, right). Myosin 5a is a versatile non-muscle central motor protein that is crucial for vesicular transport.³⁴ Here we specifically interrupted the vesicular miR-29a export by myosin 5a inhibition. In agreement with the findings after blebbistatin treatment, small interfering RNA (siRNA)-mediated knockdown of myosin 5a led to reduced miR-29a release from primary myofibroblastic HSC (Figure 2B).

Profibrogenic Stimulation Enhances Autophagy-Mediated miR-29 Release From HSC

Myosins play a versatile role in cellular vesicular transport, including the several steps of autophagy pathway including autophagy initiation, phagophore expansion, and fusion of autophagosome and lysosome.³⁶ Moreover, both TGF β and PDGF-BB can induce autophagy.^{25,27,28} Hence, we confirmed the formation of autophagosome-like structures in myofibroblastic HSC upon stimulation with TGF β and PDGF-BB using transmission electron microscopy (Figure 2D). Furthermore, the expression of the autophagosome membrane protein LC3 was highly up-regulated after TGF β treatment (Figure 2C, E, and F). These results underscore the impact of TGF β or PDGF-BB stimulation in autophagosome formation and activation of the autophagy.

Chloroquine is a potent autophagy inhibitor, blocking the fusion between autophagosomes and other vesicles.³⁷ In agreement, chloroquine treatment resulted in an increase of the activated LC3 II form (Figure 2E and F). Notably, inhibition of autophagy activity by chloroquine significantly abolished the TGF β -induced miR-29a secretion (Figure 2G).

Autophagy Induction Leads to miR-29a Secretion

Next, we studied miR-29a release during the time course of autophagy induction by TGF β and PDGF-BB. There was a continuous up-regulation of miR-29a secretion and increase of LC3 protein expression in a time-dependent manner during TGF β (Figure 3A and C) or PDGF-BB stimulation (Figure 3B and D). We also confirmed autophagy induction using cationic amphiphilic tracer dye to measure autophagic vacuoles. Flow cytometry analysis showed that the percentage of autophagic HSCs increased more than 3-fold in response to profibrogenic stimulation (Figure 3E and F). To verify that miR-29 release is related to autophagy, we treated HSC with the autophagy inducers rapamycin or torin-1 (Figure 3E and G). Importantly, an increase in miR-29a secretion into the HSC culture supernatant was confirmed after autophagy induction by rapamycin and torin-1 treatment (Figure 3A and B). Here, we show that induction of autophagy by both profibrogenic mediators and classical autophagy inducers strongly up-regulates extracellular levels of miR-29a (Figure 3A and B).




Figure 1. Intracellular and extracellular miR-29a levels of HSC in response to stimulation with TGF β or PDGF-BB. MicroRNA-29a levels and α SMA expression freshly isolated HSC (d0) in comparison with levels in HSC of early (day 1, d1) and late primary culture (day 7, d7). Expression profiles were determined in triplicates by quantitative PCR from 3 independent primary HSC preparations (A). In response to TGF β (B) or PDGF-BB (C) treatment, cellular miR-29a in immortalized HSC (HSC-T6) and extracellular miR-29a in HSC culture supernatants as well as in vesicles were quantified by real-time PCR (B and C). After stimulation by TGF β and PDGF-BB, apoptosis was determined by TUNEL analysis in HSC; DNase-treated HSCs were used as positive control. HSC were counterstained with fluorescein isothiocyanate (FITC)-conjugated phalloidin. TUNEL-positive cells are shown by red fluorescence (D). HSCs were stained with annexin V-FITC and propidium iodide and analyzed by flow cytometry (E). The percentages of apoptotic cells after TGF β , PDGF-BB, or H₂O₂ (positive control) treatment are shown. (*P value < .05) (E). Vesicular fractions from supernatants of TGF β - or PDGF-BB-stimulated HSC were characterized by immunoblotting using antibodies against EV markers, TSG101 and CD63. Calnexin was used as control for intracellular component (F). The amounts of secreted vesicles released from control HSC or TGF β or PDGF-BB treated HSC were estimated by protein determination of the respective extracellular vesicular fractions (G). Moreover, isolated vesicles were imaged by electron microscopy (H) and the nanoparticle tracking method (I).

Therefore, miR-29a release is not specific to profibrogenic stimulation but rather to induction of autophagy, which is stimulated either by profibrogenic mediators (TGF β and PDGF-BB) or by other autophagy-inducing agents.

Furthermore, fluorochrome-labeled miR-29a, transfected into HSC-T6, co-localized with cellular LC3 (Figure 3H), indicating that after profibrogenic stimulation vesicular miR-29a release is strongly associated to its recruitment into autophagosomes.




Figure 2. Stimulation of HSC fibrogenesis by PDGF-BB and TGF β leads to miR-29a secretion and enhanced autophagy. HSC-T6 cells were treated with TGF β in combination with or without blebbistatin inhibition. Both the cellular and supernatant RNA was isolated, and real-time PCR was performed to analyze intracellular and extracellular miR-29a levels (A). After treatment of primary HSCs (on day 7 after isolation) with siMyosin 5a, intracellular and extracellular miR-29a levels, quantified by PCR, were shown (B). Cells, nonstimulated or stimulated with TGF β , were immunostained with LC3 antibodies and subsequently imaged by confocal microscopy (*blue* = DAPI, *red* = LC3 protein, scale bar = 15 μ m (C)). Transmission electron microscopy revealed autophagosome formation in HSCs in response to PDGF-BB and TGF β treatment (D). LC3 protein expression was shown by immunoblotting using cell lysates from HSCs, nontreated (control), treated with TGF β , or treated with both TGF β and chloroquine (CQ) (E and F). Cellular miR-29a levels were determined by qPCR showing that miR-29a decrease upon TGF β treatment was blocked when HSC were also treated with chloroquine (G). (*P* value * $<.05$, ** $<.001$).

Autophagy Inhibition Leads to Immense Increment of Intracellular miR-29a

Because miR-29a acts as an antifibrotic miRNA that targets ECM gene expression, we hypothesized that inhibition of autophagy would lead to elevated cellular HSC miR-29a levels, followed by a decrease in miR-29a targeted genes such as the Col1A1 subunit and PDGF-C. In agreement with previous data showing that miR-29 targets ECM synthesis,^{15–18} we first proved that miR-29a overexpression leads to a significantly reduced expression of the collagen subunit *Col1A1* in primary HSC (Figure 4A) without changing the myofibroblastic HSC morphology (Figure 4B).

The ATGs play an indispensable role in autophagosome formation. ATG5 and ATG7 are crucial for initiation of autophagy.³⁸ To strengthen the link between autophagy and enhanced secretion of miR-29a, we knocked down either ATG5 or ATG7 expression in combination with TGF β treatment. Strikingly, treatment with small interfering ATG5 or small interfering ATG7 significantly neutralized the TGF β -induced decrease of cellular miR-29a (Figure 4C).

Whereas chloroquine functions mainly by blocking maturation of vesicles and disrupts autophagosome fusion with other vesicles,³⁷ other autophagy inhibitors interfere with autophagy initiation, phagophore expansion, or autophagosome formation. Because autophagy initiation requires the deactivation of mammalian target of rapamycin (mTOR), which is crucial requirement for autophagy, MHY-1485, acting as the mTOR activator, has been widely used to inhibit autophagy. The elongation of phagophores is controlled by kinase activity of PI3K III and formation of beclin1-VPS34 and ULK1 complex. 3-Methyladenine functions as an autophagy inhibitor by targeting PI3K III, whereas bafilomycin inhibits vacuolar H⁺ ATPase of lysosomes to suppress their acidification (Figure 4D). We used the autophagy inhibitors 3-methyladenine, bafilomycin, chloroquine, MHY-1485, MRT68921, wortmannin, and LY-294002 (Table 1, Figure 4D). Notably, all of the inhibitors blocked miR-29a secretion, showing as significant recovery of the cellular miR-29a levels (Figure 4E). By interfering with lysosomal fusion, chloroquine and bafilomycin especially markedly inhibited cellular miR-29a loss.




Figure 3. Time course of miR-29a release from HSC after TGF β or PDGF-BB stimulation. Extracellular miR-29a levels were analyzed by real-time PCR (A and B), and LC3 protein immunofluorescence staining (C and D) was performed after 0, 4, 8, 12, 16, 20, and 24 hours of TGF β (A and C) or PDGF-BB (B and D) treatment of HSC-T6 cells. Moreover, autophagosomes were stained by cationic amphiphilic tracer dye followed by fluorescence-activated cell sorter analysis (E). The percentages of autophagy-positive cells are presented in the bar diagram. (** $P < .001$; data from 3 representative experiments are displayed) (F). Rapamycin and Torin-1 treatment for 24 hours were used as positive controls (G). Cy3-labeled miR-29a (red) was transfected, and colocalization with LC3 protein (green) expression was monitored after LC3 immunocytochemistry (scale bar = 15 μ m) (H).

MicroRNA-29 acts as an antifibrotic miRNA because it targets transcripts that encode ECM proteins such as different collagens but also profibrogenic mediators such as PDGF-C.^{15,16,30,31,39} The enhanced cellular miR-29a levels, caused by autophagy inhibition (Figure 4E), resulted in a significant down-regulation of the miR-29a target genes, *Col1A1* and *PDGF-C* (Figure 4F and G). However, the inhibition of the TGF β -mediated effects on the two miR-29 targets differed between autophagy inhibitors and was less pronounced on *PDGF-C* expression than on *Col1A1* expression. Interestingly, chloroquine showed the strongest restoration of cellular miR-29a, but in contrast to bafilomycin and the PI3K inhibitors, it did not markedly influence *Col1A1* or *PDGF-C* expression (Figure 4E–G). Although besides the miR-29a control, the regulation of miR-29a targeted genes is suggested to underlie additional mechanistic links, our findings definitively show that autophagy inhibition repressed the *Col1A* and *PDGF-C* expression by restoring miR-29a function.

Increased Circulating miR-29a Levels During Liver Fibrosis

To determine whether autophagic flux-mediated miR-29 release is increased during fibrogenesis, we quantified miR-29a levels in liver and serum from a mouse CCl₄ fibrosis model and in clinical samples from patients with chronic HCV. Hepatic miR-29a levels were down-regulated in mice treated with CCl₄ for 4 weeks, whereas miR-29a in corresponding serum samples were up-regulated more than 5-fold (Figure 5A). In addition, we observed a

significant overexpression of LC3 protein in livers of CCl₄-treated mice, indicating that autophagic activity was strongly intensified during CCl₄-induced fibrogenesis (Figure 5B).

Next, we analyzed 84 human biopsies representing different stages of fibrosis during chronic HCV infection ($N_{F0} = 2$, $N_{F1} = 23$, $N_{F2} = 26$, $N_{F3} = 22$, $N_{F4} = 11$, and one not specified sample). Patients' clinical datasets were previously described by Trebicka et al⁴⁰ and Wedemeyer et al.⁴¹ In agreement with the data in murine fibrosis, there was a loss of miR-29a in liver biopsies, showing inflammation and fibrosis (Figure 6A). Notably, by α SMA and LC3 double staining, we demonstrated active autophagy within myofibroblastic HSC in the fibrotic septa of liver biopsies with chronic hepatitis C (Figure 6B).

For circulating miR-29 quantification, 44 matching serum samples ($N_{F1} = 10$, $N_{F2} = 13$, $N_{F3} = 11$, $N_{F4} = 10$) were collected. Serum miR-29a levels in patients with hepatitis C were highly elevated compared with healthy controls ($N = 12$) but did not correlate with alanine aminotransferase values (data not shown). Importantly, significantly elevated miR-29a levels were strongly associated with the severity of fibrosis (Figure 6B). Receiver operating characteristic analysis reinforced the potential of fibrosis-associated miR-29 release as a biomarker of chronic liver disease progression and fibrosis (Figure 6C).

Discussion

The miR-29a acts as an antifibrotic miRNA in fibroblasts and fibroblast-related cell types and is crucial in




Figure 4. Inhibition of autophagy blocks TGF β -induced miR-29a secretion and up-regulates miR-29a target gene expression. MicroRNA-29a and Col1A1 gene expression levels were quantified in freshly isolated HSC (d0) or in cultured primary HSC after transgenic overexpression of miR-29a in comparison with non-transfected primary HSC or transfected with scramble RNA (scr). HSC were transfected with miR-29a mimic RNA or scr RNA at days 4 and 6 and harvested 72 hours after transfection. Transgenic miR-29a mimic expression leads to Col1A1 down-regulation (A). Mouse HSC at day 7, fixed 72 hours after transfection with scramble or miR29a, were stained with phalloidin (green) and anti-desmin antibodies (red). Nuclei were stained with DAPI, and collagen1 is shown in aqua blue after immunostaining with anti-collagen 1 antibodies. There were no morphologic changes observed after miR-29 treatment (B). ATG5 and ATG7 expression in HSC-T6 cells treated with siATG5 (50 nmol/L) or siATG7 (50 nmol/L), respectively, versus scramble siRNA was analyzed by quantitative PCR, showing efficient ATG5 and ATG7 inhibition. Quantitative PCR of cellular miR-29a levels proved that ATG5 and ATG7 blockade after siRNA treatment (siATG5, siATG7) restored the TGF β -stimulated repression in scramble treated HSC-T6 (C). The working mechanisms of autophagy inhibitors are illustrated (D). Briefly, sufficient amino acid supply (or other cytoplasmic changes) sustains the activity of mTOR, the latter of which prevents the induction of autophagy ①. The elongation of phagophores requires the activity of PI3K III and formation of Beclin1/VPS34 and ULK1 complex. After formation of autophagosomes ②, they fuse alternatively with lysosomes to form auto-lysosomes ④, merge with endosomes to form multivesicular bodies ③, or form amphisomes, which ultimately leads to the secretion of EV ⑤. Intracellular miR-29a expression levels were analyzed after dual treatment with TGF β and different autophagy inhibitors MHY1485, 3-MA, wortmannin, LY294002, MRT68921, bafilomycin A1, chloroquine (E). MicroRNA-29a target genes, Col1A1 (F) and PDGF-C (G), were determined in response to TGF β stimulation and diverse autophagy inhibition. The induction of Col1A1 and PDGF-C after TGF β is indicated by the dashed line (F and G). (*P* value * $<.05$, ** $<.001$).

suppressing ECM synthesis.^{16,19} During HSC activation, hepatic miR-29a is gradually decreased in parallel with enhanced production of ECM and autocrine TGF β

stimulation.^{19,31} TGF β is a prominent stimulus that induces ECM production and provokes loss of miR-29 from fibroblasts as shown in different organs.^{16,19}

Table 1. Autophagy Inhibitors and Inducers

Chemical reagent	Working concentration	Function (references)	Sites of target in autophagy signaling
Chloroquine	50 $\mu\text{mol/L}$	Autophagy inhibitor	Autophagosome maturation
Bafilomycin	50 nmol/L	Autophagy inhibitor	V-type ATPase inhibitor
MRT68921	1 $\mu\text{mol/L}$	Autophagy inhibitor	ULK1 complex
LY-294002	10 mmol/L	Autophagy inhibitor	Class I and Class III PI3K
3'-MA	5 mmol/L	Autophagy inhibitor	Class I and Class III PI3K
Wortmannin	50 nmol/L	Autophagy inhibitor	Class I and Class III PI3K
MHY1485	2 $\mu\text{mol/L}$	Autophagy inhibitor	mTOR
Torin-1	5 $\mu\text{mol/L}$	Autophagy inducer	mTOR
Rapamycin	100 ng/mL	Autophagy inducer	mTOR

In this study, we provide compelling evidence that the profibrogenic mediators TGF β and PDGF-BB strongly stimulate vesicular miR-29a secretion from HSC, the principal collagen-producing cells in liver injury. Because miR-29a targets mRNA transcripts of a wide spectrum of ECM members such as different collagen subunits, elastin, and fibrillin 1, resulting in less ECM accumulation and fibrosis,^{11,15-19} increase of cellular miR-29a in HSC by inhibition of TGF β and PDGF-BB mediated release of cellular miR-29a is of high therapeutic relevance. Indeed treatment of HSC with miR-29a mimics and subsequent miR-29a overexpression leads to less ECM expression and less fibrosis.⁴²

Vesicles released after profibrogenic stimulation of HSC with TGF β and PDGF-BB had the size of small EV^{32,33} and contained the exosome markers TSG101 and CD63, which are part of tetraspanin protein family⁴³ and endosome sorting complex required for transport,⁴⁴ respectively. Recently EV release has been demonstrated as a consequence of cellular autophagy, although the mechanistic links are not yet fully understood.⁴⁵⁻⁴⁷ Conventional autophagy is regarded as a degradation process in which autophagosomes fuse with lysosomes, leading to the turnover of their contents. However, unconventional autophagy processes activate secretory pathways, resulting in cytokine secretion that does not involve the Golgi apparatus.^{48,49} TGF β and PDGF-BB are both potent autophagy inducers, which is consistent with the finding that autophagy induces HSC

activation, the initiation of myofibroblast trans-differentiation, and subsequently liver fibrosis.^{25,26,50} Thus, inhibition of autophagy by rapamycin treatment abrogated the marked increase of procollagen synthesis during murine CCl₄-induced fibrosis, supporting our results of an autophagy-miRNA secretion that mediates miR-29a loss and enhanced ECM synthesis. Furthermore, autophagy inhibition in HSC in vivo by stellate cell-specific knockout of the *ATG7* gene resulted in alleviated fibrosis.²⁶ Autophagy induction by TGF β is based on its interaction with insulin-like growth factor binding protein-associated protein 1 and activation of the PI3K/AKT/mTOR pathway.⁵¹ In addition, autophagy is induced by hypoxic and endoplasmic reticulum stress in response to metabolic starvation during fibrogenesis.⁵² Although HSC-specific inhibition of autophagy retards fibrosis progression,²⁶ its therapeutic application is challenging because of the different influences on the different hepatic cell types. Thus, autophagy is beneficial in hepatocytes such that global autophagy inhibition in liver could be deleterious.^{21,22} Moreover, inhibition of autophagy in hepatocytes leads to development of hepatocellular carcinoma.^{23,24} Therefore, the therapeutic impact of inhibition of miR-29a release from HSC to the bloodstream should be ideally shown on experimental fibrosis in HSC-specific, autophagy-deficient mice. After demonstration in vitro that the interruption of the autophagy pathway in HSC leads to cellular miR-29 accumulation, followed by retardation of ECM synthesis, in vivo studies on the miR-29a/autophagy




Figure 5. Hepatic LC3 overexpression in murine fibrosis is associated with miR-29a release in the serum. After 4 weeks of CCl₄ intoxication fibrosis was developed, and total RNA was isolated from both liver and serum samples of CCl₄-treated mice (n = 6) or control mice (n = 6). Liver and serum miR-29a levels were quantified by real-time PCR (A). LC3 protein expression levels were determined by immunoblotting and subsequent analysis using quantitative chemiluminescent imaging (B). (P value * < .05, ** < .001).




Figure 6. Autophagy-associated miR-29a secretion into circulation is a biomarker of fibrosis. MicroRNA-29a levels in 85 biopsy specimens that represent different stages of inflammation (G1–G3) and fibrosis (F0–F4) (A). Localization of the LC3 protein (*brown*) in SMA-positive myofibroblastic cells (*red*) was found mainly in fibrotic septa (*closed arrows*). LC3-positive hepatocytes are shown by *open arrows* (B). MicroRNA-29a levels in 56 serum samples including 12 healthy volunteers and 44 patients with different grades of inflammation (G1–G3) or different stages of fibrosis (F1–F4) (C). Whereas hepatic miR-29a levels were significantly reduced in biopsies of fibrotic livers ($P = .041$) (A), the circulating miR-29a was distinctly increased in serum samples of patients with chronic hepatitis C ($P = .004$), depending on the severity of fibrosis (F2–F4) (C). Receiver operating characteristic curve analysis for serum miR-29a as the continuous variable and inflammation (G1–3) or progression of fibrosis (F1/F2–F4) as target variables is shown in (D). (P value $^* < .05$, $^{**} < .001$).

axis will be of high relevance for therapeutic strategies of fibrosis prevention.

In conclusion, autophagy-regulated processes are multifaceted, including nonconventional autophagy pathways that link autophagy-related signalling to the endocytotic and exocytotic pathway and EV secretion. Hence, the autophagy marker protein LC3 was also identified in late endosomes and multivesicular bodies.⁵³ Importantly, PDGF has been discovered to promote exosomal protein secretion due to the mTOR pathway activation.⁵⁴ In addition, the recent findings of Gao et al⁵⁴ show that PDGF-induced vesicular release may be blocked by mTOR pathway inhibition, followed by canonical autophagy activation. These findings led us to suspect that the autophagy-related EV secretion involves endosomes and multivesicular bodies of the endocytotic and exocytotic network and that it competes with the canonical autophagy progress, which results in lysosomal degradation. Indeed, in cancers, the release of EVs is negatively regulated by induction of canonical autophagy pathways.⁵⁵ In our study, we now prove that the interaction of autophagy processes with the endocytotic and exocytotic pathway is involved in miR-29a release.

It is noteworthy that autophagy-regulated pathways leading to fibrosis-associated vesicular release of miR-29a were illustrated in clinical samples of HCV patients with injury and fibrosis. In those tissue and serum samples, miR-29 reduction in the tissue corresponds to increase of that at serum levels, which is consistent with the progression of liver fibrosis.¹⁹ In summary, our findings point to an autophagy-related secretory pathway that controls the release of miR-29a, similar to its effects on cytokine secretion.^{48,49} Importantly, the controlled miRNA release is regulated by autophagy, linking this process to endocytotic and exocytotic flux that culminates in vesicular secretion.

Materials and Methods

Cell Culture and Stimulation of HSC

Primary mouse HSC were isolated from male BALB/c mice and retired breeder rats after liver perfusion and Nycodenz density centrifugation as previously described.⁵⁶ Primary HSC were incubated in Dulbecco modified Eagle medium (DMEM) with 20% fetal calf serum (FCS) and supplemented with 2% penicillin for the first 2 days after

isolation. Then, HSC were sustained in DMEM with 10% FCS. Myofibroblastic transition was characterized by α SMA induction. HSC at 36 hours were considered as quiescent compared with HSC on day 7 when cells express high levels of α SMA, therefore considering them as myofibroblastic cells.

HSC-T6 cells were cultured in DMEM containing 10% fetal bovine serum as previously described.⁵⁷ HSC were stimulated with 30 ng/mL PDGF-BB (Sigma-Aldrich, Taufkirchen, Germany) or 5 ng/mL TGF β (R&D Systems, Wiesbaden-Nordenstadt, Germany). For additional stimulation, cells were incubated for 2 hours with medium containing 50 μ mol/L blebbistatin (Sigma-Aldrich Chemie GmbH, Munich, Germany) and then with TGF β for additional 24 hours. For autophagy induction and inhibition, reagents are summarized in Table 1. Autophagy was monitored by fluorescence microscopy or quantified using the cationic amphiphilic tracer dye followed by flow cytometry.

Autophagy Induction and Inhibition

Cells were seeded in 6-well plates in DMEM containing 10% FCS. The next day, the medium was changed to DMEM containing 0.5% FCS. Cells were incubated in DMEM without FCS before stimulating with 5 ng/mL TGF β (R&D Systems) or 30 ng/mL PDGF-BB (Sigma-Aldrich) for 24 hours. As positive control for autophagy activation, rapamycin or torin1 treatment was performed according to the concentrations listed in Table 1. For autophagy inhibition, 4 hours after TGF β stimulation, agents listed in Table 1 were added.

For autophagy inhibition using different siRNAs (Table 2), cells were transfected with 50 nmol/L siRNA using lipofectamine (Thermo Fisher, Germany) according to the manufacturer's instructions. After 24 hours, HSC were stimulated with TGF β or PDGF-BB for another 24 hours and then lysed either for RNA isolation or for protein expression analysis.

Autophagy Analysis by Flow Cytometry

After profibrogenic stimulation, cells were stained with cationic amphiphilic tracer dye using CYTO-ID autophagy detection kit (Enzo Life Sciences, Lörrach, Germany). Subsequently, fluorescence was analyzed by flow cytometry

using FACS Aria III (Becton Dickinson, Heidelberg, Germany).

Vesicle Preparations, Negative Staining, and Electron Microscopy

Supernatant of HSC was collected after stimulation for 24 hours, and 250 μ L was taken for vesicle preparation using the Exosome Precipitation Solution (SBI, Mountain View, CA) according to the manufacturer's instructions. The vesicle pellets were dissolved in 25 μ L phosphate-buffered saline and used for miRNA quantification, protein determination by the BCA protein assay (Pierce, Thermo Scientific, Rockford, IL), or negative staining.

For negative staining, 20 μ L of vesicle suspension was placed on carbon-coated grids and blotted on filter paper after washing with an aqueous solution of 2% uranyl acetate. Transmission electron microscopy of HSC upon TGF β and PDGF-BB stimulation was performed as previously described.⁵⁸ Then, cells were trypsinized and centrifuged after stimulation. Cell pellets were fixed by glutaraldehyde solution and incubated in osmium tetroxide (OsO₄) solution. After dehydration through different ethanol concentrations, cell pellets were embedded by a tissue-embedding machine (Leica, Wetzlar, Germany; EM TP). Ultrathin sections were stained with lead citrate and uranyl citrate. Uranyl acetate stained vesicles and ultrathin sections were monitored by electron microscopy using the EM902A (Zeiss, Oberkochen, Germany).

Nanoparticle Tracking Analysis

Cell culture supernatants were collected after 24 hours with or without TGF β stimulation. A series of centrifugation was performed to remove dead cells and debris as described previously.⁵⁹ After 0.22 μ m filtration, the supernatants were taken for vesicle isolation exoEasy Maxi Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Directly after isolation, vesicles were diluted 1:1000 in phosphate-buffered saline and imaged by Nanosight Range NS300 (Malvern, Kassel, Germany).

Detection of Cell Death and Apoptosis

HSC were starved for 24 hours before stimulation. After 24 hours of starvation, cells were centrifuged and washed

Table 2. mRNA Sequences Targeted by siRNA

siRNA	Company	Target mRNA sequences
Rat siATG5	Dharmacon, USA	(a) AGUCAGGUGAUC AACGAAA (b) CGUGUGGUUUGGACGGAAU (c) GGAUGAGAU AACUGAACGA (d) ACCGGAACUCAUGGAAUA
Rat siATG7	Dharmacon, USA	(a) CAAAGUUAACAGUCGGUGU (b) AGUGAAUGCCAGAGGGUUC (c) CUGGAGGAACUCAUUGAUA (d) CCCAGAAGAAGUUGAACGA
Rat Myosin 5a	Dharmacon, USA	- CGCUACAAGAAGCUCCAUA

twice with cold phosphate-buffered saline and stained with annexin V-FITC and propidium iodide for 15 minutes, followed by flow cytometry analysis (FACS Aria III; Becton Dickinson). Cells treated with 100 $\mu\text{mol/L}$ hydrogen peroxide were used as positive control.

In addition, cells were analyzed for apoptosis by TUNEL assay using the cell death detection kit from Roche Diagnostics (Mannheim, Germany) following the recommendation of the manufacturer. DNase treatment (1 U/mL) was taken as positive control. TUNEL-positive cells are shown by red fluorescence. After TUNEL staining, cells were counterstained by FITC-conjugated phalloidin (Sigma-Aldrich, Heidelberg, Germany) and monitored by a Nikon (Tokyo, Japan) Eclipse T2 microscope.

Induction of Acute Liver Injury and Fibrosis

In this study, 12 BALB/c male mice (25–35 g) were used, from which 6 were subjected to CCl_4 injury and 6 control mice were treated only with mineral oil as described earlier.^{25,39} All experiments were performed under the supervision of the National Health and Medical Research Committee Guidelines for Animal Experimentation. Liver tissues were taken and snap-frozen in liquid nitrogen for RNA isolation and hydroxyproline determination as described before. Liver tissue chosen from liver segment IV was fixed in 4% buffered paraformaldehyde and embedded in paraffin for histopathologic evaluation.

Patients, Human Biopsies, and Serum Specimens

A total of 85 patients with well-documented chronic hepatitis C infection were selected from the database of HepNet, the German Competence Network on Viral Hepatitis (www.kompetenznetz-hepatitis.de). All patients gave their written advised consent before undergoing liver biopsy. Clinical characteristics of the cohort were previously reported by Wedemeyer et al.⁴¹ Briefly, the cohort included 57.14% men and 42.86% women; 78% of the patients were positive for HCV genotype 1 and 19% for genotype 3.

For grading of inflammation (G1–G4) and staging of fibrosis (F0–F4), histologic assessment was performed independently by 2 experienced pathologists (UD, HPD) according to the method of Desmet et al.⁶⁰ From a total of 85 biopsies ($N_{\text{total}} = 85$) representing different stages of fibrosis ($N_{\text{F0}} = 2$, $N_{\text{F1}} = 23$, $N_{\text{F2}} = 26$, $N_{\text{F3}} = 22$, $N_{\text{F4}} = 11$, and one not specified sample), RNA was extracted and used in this study.

For circulating miR-29 quantification, 56 serum specimens including 12 samples of healthy blood donors and 44 samples of chronic hepatitis C patients with fibrosis ($N_{\text{F1}} = 10$, $N_{\text{F2}} = 13$, $N_{\text{F3}} = 11$, $N_{\text{F4}} = 10$) were available and used for RNA isolation as described above.

Total RNA Extraction

Intracellular total RNA from snap-frozen tissues or cells was isolated using the Qiazol reagent following the instructions of the supplier (Qiagen, Hilden, Germany).

Extracellular RNA was isolated from cell culture supernatants, vesicle fractions, or serum samples of patients with chronic hepatitis C liver disease. Cell culture supernatants were collected from HSC with or without stimulation, centrifuged at 12,000g for 20 minutes, and filtered through 0.22 μm filters. Then, 200 μL of filtered supernatants, vesicle fractions, or serum samples from patients or mice were applied to RNA isolation using Qiazol. For quality control and later normalization, we added 2 pmol spike SV-40 RNA to all extracellular specimens before RNA isolation as previously described.⁴⁰

The quantity of RNA obtained from cells and tissues was determined by A_{260} -measurement using the ND-1000 NanoDrop spectrophotometer (NanoDrop, Wilmington, DE), and the quality was assessed by microcapillary electrophoresis (2100 BioAnalyser; Agilent Technologies, Waldbronn, Germany).

Total RNA preparations from human formalin-fixed and paraffin-embedded biopsies were performed according to previous reports.^{61,62}

Intracellular and Extracellular miRNA Quantification by Quantitative Real-Time Polymerase Chain Reaction

RNA was polyadenylated and reverse transcribed by means of miScript II reagents from Qiagen. Subsequently, miRNA was analyzed by quantitative polymerase chain reaction (PCR) using the miRNA-SYBR Green PCR Kit (Qiagen). Primers used for cDNA synthesis and real-time PCR were selected and purchased from the GeneGlobe Search Center (Qiagen) (Table 3). All steps were performed in triplicate and in agreement with the supplier's guidelines.

Cellular miRNA levels were normalized using RNU6 as reference. For normalization of extracellular miRNA levels, SV40-miRNA (Qiagen), which has been added to serum samples, vesicle fractions, and cell culture supernatants before the RNA isolation procedure, was used.

Analysis of mRNA Expression by Real-Time PCR

After polyadenylation and reverse transcription using the Qiagen miScript reverse transcription kit as described above, 2 ng cDNA was applied to real-time PCR assays using the GoTaq qPCR Master Mix (Promega, Walldorf, Germany) and primer sets listed in Table 3. Real-time PCR was performed in triplicates on a Bio-Rad (Hercules, CA) C1000^M thermal cycler. After demonstration that primer sets exert equal and high efficiencies, relative expression was calculated by the $\Delta\Delta\text{Ct}$ method using the transcript levels of hypoxanthine-guanine phosphoribosyl transferase for normalization.

siRNA Transfection

Cells were seeded in 6-well plates in DMEM containing 10% FCS. After reaching 30% confluency, cells were transfected using the X-tremeGENE transfection reagent (Sigma-Aldrich, Taufkirchen, Germany). A mix of siRNAs

Table 3. Primers Used for Quantitative PCR

Oligonucleotide	Sequence	Company
mo Atg5-F	CTG TTC GAT CTT CTTGCATCA	Eurofins MWG, GER
mo Atg5-R	TCC TTT TCT GGA AAA CTC TTG AA	Eurofins MWG, GER
mo Atg7-F	CTT GGC TGC TAC TTC TGC AA	Eurofins MWG, GER
mo Atg7-R	AGT CCG GTC TCT GGT GGA A	Eurofins MWG, GER
mo mTOR-F	ATC AAG CAA GCG ACA TCT CA	Eurofins MWG, GER
mo mTOR-R	CAG GCC TTG GTT ACC AGA A	Eurofins MWG, GER
mo coL1A1A-F	CAT GTT CAG CTT TGT GGA CCT	Eurofins MWG, GER
mo coL1A1A-R	GCA GCT GAC TTC AGG GAT GT	Eurofins MWG, GER
mo PDGF-C-F	GCG GAA GCG CAT CTA TAT CT	Eurofins MWG, GER
mo PDGF-C-R	AAT GAA TAG GTC CTC AGA GTC CA	Eurofins MWG, GER
mo HPRT-F	GAC CGG TTC TGT CAT GTC G	Eurofins MWG, GER
mo HPRT-R	ACC TGG TTC ATC ATC ACT AAT CAC	Eurofins MWG, GER
miR-29a		Qiagen, GER
RNU6		Qiagen, GER
Universal primer		Qiagen, GER
SV40-miRNA		Qiagen, GER

GER, Germany.

(Dharmacon Inc, Lafayette, CO) targeting the respective transcript of interest (Table 1) was used for transfection following the manufacturer's instructions.

Immunoblotting

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed by means of the Bio-Rad Mini protein gel system. Briefly, protein samples were loaded with Laemmli sample buffer, heat-denatured, and directly loaded onto the gels. After electrophoresis and protein transfer, PCDF membranes were blocked in 10% milk powder solution. After incubation with the first antibodies (Table 4), membranes were incubated with the respective peroxidase-conjugated secondary antibodies, and then membranes were developed using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, Germany) according to the manufacturer's instructions. Signals were evaluated using the ChemiDoc Imaging System (Bio-Rad).

Immunofluorescence Staining and Immunohistochemistry

HSC were plated in chamber slides, and after 24 hours of starvation without FCS, they were treated with either TGF β or PDGF-BB. After stimulation, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (pH 8.0) and stained with rabbit LC3 antibody (Abcam, Cambridge, MA), secondary antibody, goat anti-rabbit immunoglobulin G conjugated with Alexa 488 (Abcam), according to manufacturer's instructions. In addition, primary HSC were immunostained with anti- α SMA, anti-desmin, and anti-collagen I antibodies listed in Table 4. Cells were analyzed by confocal laser scanning microscopy (Leica TCS SP8; Leica Microsystems).

Serial sections of formalin-fixed and paraffin-embedded liver biopsies from patients with chronic hepatitis C infection were applied to LC3 and α SMA immunocytochemistry (Table 4) using BOND IHC/ISH Staining Instruments (Leica Biosystems, Wetzlar, Germany) according to the

Table 4. Antibodies Used in This Study

Targeted antigen	Company	Dilution (immunoblotting)	Dilution (immunochemistry)
LC3B	Abcam, USA	1:1000	1:1000
SQSTM1/p62	Abcam, USA	1:1000	—
β -actin	Sigma-Aldrich, GER	1:1000	—
ATG7	Abcam, USA	1:1000	—
α -SMA	DAKO, GER	—	1:400
Phalloidin	Thermo Scientific	—	1:500
Collagen1	Southern Biotech	—	1:50
Desmin	Thermo Scientific	—	1:200

manufacturer's instructions. For double staining, LC3 immunodetection was developed using peroxidase-polymer conjugated secondary antibodies and diaminobenzidine as substrate, whereas SMA was detected by means of phosphatase-linked anti-mouse antibodies and new fuchsin (pararosaniline) as substrate, using the BOND Polymer Refine Detection kit (Leica Biosystems).

References

- Altamirano-Barrera A, Barranco-Fragoso B, Mendez-Sanchez N. Management strategies for liver fibrosis. *Ann Hepatol* 2017;16:48–56.
- Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol* 2011;6:425–456.
- Gabele E, Brenner DA, Rippe RA. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. *Front Biosci* 2003;8:d69–d77.
- Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. *Nat Rev Nephrol* 2016;12:325–338.
- Zhang YE. Non-Smad pathways in TGF-beta signaling. *Cell Res* 2009;19:128–139.
- Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-beta 1 gene expression in human liver disease. *J Hepatol* 1992;14:259–264.
- Czaja MJ, Weiner FR, Flanders KC, Giambone MA, Wind R, Biempica L, Zern MA. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. *J Cell Biol* 1989;108:2477–2482.
- Yoshida K, Matsuzaki K. Differential regulation of TGF-beta/Smad signaling in hepatic stellate cells between acute and chronic liver injuries. *Front Physiol* 2012;3:53.
- Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. *J Clin Invest* 1989;84:1786–1793.
- Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium: direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. *J Clin Invest* 1989;84:1780–1785.
- Sekiya Y, Ogawa T, Yoshizato K, Ikeda K, Kawada N. Suppression of hepatic stellate cell activation by microRNA-29b. *Biochem Biophys Res Commun* 2011;412:74–79.
- Jiang Y, Zhao Y, He F, Wang H. Artificial microRNA-mediated Tgfb2 and Pdgfrb co-silencing ameliorates carbon tetrachloride-induced hepatic fibrosis in mice. *Hum Gene Ther* 2019;30:179–196.
- Patel DJ, Ma JB, Yuan YR, Ye K, Pei Y, Kuryavyi V, Malinina L, Meister G, Tuschl T. Structural biology of RNA silencing and its functional implications. *Cold Spring Harb Symp Quant Biol* 2006;71:81–93.
- Aravin A, Tuschl T. Identification and characterization of small RNAs involved in RNA silencing. *FEBS Lett* 2005;579:5830–5840.
- van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. *Proc Natl Acad Sci U S A* 2008;105:13027–13032.
- Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, Strack I, Molnar L, von Brandenstein M, Tox U, Nischt R, Coutelle O, Dienes HP, Odenthal M. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. *PLoS One* 2011;6:e24568.
- Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. *Arthritis Rheum* 2010;62:1733–1743.
- Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, Thannickal VJ, Cardoso WV, Lu J. MiR-29 is a major regulator of genes associated with pulmonary fibrosis. *Am J Respir Cell Mol Biol* 2011;45:287–294.
- Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. *Hepatology* 2011;53:209–218.
- Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Mollnow T, Zimmermann HW, Koch A, Hellerbrand C, Weiskirchen R, Frey N, Tacke F, Trautwein C, Luedde T. MiR-133a mediates TGF-beta-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. *J Hepatol* 2013;58:736–742.
- Weiskirchen R, Tacke F. Relevance of autophagy in parenchymal and non-parenchymal liver cells for health and disease. *Cells* 2019;8:16.
- Gracia-Sancho J, Guixé-Muntet S. The many-faced role of autophagy in liver diseases. *J Hepatol* 2018;68:593–594.
- Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N. Autophagy-deficient mice develop multiple liver tumors. *Genes Dev* 2011;25:795–800.
- Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. Autophagy suppresses tumorigenesis through elimination of p62. *Cell* 2009;137:1062–1075.
- Thoen LF, Guimaraes EL, Dolle L, Mannaerts I, Najimi M, Sokal E, van Grunsven LA. A role for autophagy during hepatic stellate cell activation. *J Hepatol* 2011;55:1353–1360.
- Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Czaja MJ, Friedman SL. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology* 2012;142:938–946.
- Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF-beta in hepatic stellate cell activation and liver fibrogenesis-updated 2019. *Cells* 2019;8:1419.
- Ghavami S, Cunnington RH, Gupta S, Yeganeh B, Filomeno KL, Freed DH, Chen S, Klonisch T, Halayko AJ, Ambrose E, Singal R, Dixon IM. Autophagy is a regulator of TGF-beta1-induced fibrogenesis in primary human atrial myofibroblasts. *Cell Death Dis* 2015;6:e1696.

29. Ye HL, Zhang JW, Chen XZ, Wu PB, Chen L, Zhang G. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. *Life Sci* 2019; 242:117175.
30. Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. *PLoS One* 2012;7: e33766.
31. Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U, Nischt R, Dienes HP, Odenthal M. Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. *Lab Invest* 2012;92:978-987.
32. Maji S, Matsuda A, Yan IK, Parasramka M, Patel T. Extracellular vesicles in liver diseases. *Am J Physiol Gastrointest Liver Physiol* 2017;312:G194-G200.
33. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borrás FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MA, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Gorecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzas EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekstrom K, El Andaloussi S, Elie-Caille C, Erdbrugger U, Falcon-Perez JM, Fatima F, Fish JE, Flores-Bellver M, Forsonits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielson S, Gamez-Valero A, Gardiner C, Gartner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Gorgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinke DJ 2nd, Kornek M, Kosanovic MM, Kovacs AF, Kramer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lasser C, Laurent LC, Lavieu G, Lazaro-Ibanez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Line A, Linnemannstons K, Llorente A, Lombard CA, Lorenowicz MJ, Lorincz AM, Lotvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, Moller A, Moller Jorgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loughlin A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Ostergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzi N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Saa P, Sahoo S, Salas-Huenuleo E, Sanchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schoyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL 2nd, Soares RP, Sodar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot E, Verweij FJ, Vestad B, Vinas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yanez-Mo M, Yin H, Yuana Y, Zappulli V, Zarubova J, Zekas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles* 2018;7: 1535750.
34. Langford GM. Myosin-V, a versatile motor for short-range vesicle transport. *Traffic* 2002;3:859-865.
35. Liu Z, van Grunsven LA, Van Rossen E, Schroyen B, Timmermans JP, Geerts A, Reynaert H. Blebbistatin inhibits contraction and accelerates migration in mouse hepatic stellate cells. *Br J Pharmacol* 2010;159:304-315.
36. Kruppa AJ, Kendrick-Jones J, Buss F. Myosins, actin and autophagy. *Traffic* 2016;17:878-890.
37. Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M, Reggiori F.

- Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. *Autophagy* 2018; 14:1435–1455.
38. Mizushima N. Autophagy: process and function. *Genes Dev* 2007;21:2861–2873.
 39. Mannaerts I, Eysackers N, Onyema OO, Van Beneden K, Valente S, Mai A, Odenthal M, van Grunsven LA. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. *PLoS One* 2013;8:e55786.
 40. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. *J Hepatol* 2013;58:234–239.
 41. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, Gerken G, Gieseler RK, Dienes HP, Canbay A. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. *J Hepatol* 2009;50:140–149.
 42. Matsumoto Y, Itami S, Kuroda M, Yoshizato K, Kawada N, Murakami Y. MiR-29a assists in preventing the activation of human stellate cells and promotes recovery from liver fibrosis in mice. *Mol Ther* 2016; 24:1848–1859.
 43. Andreu Z, Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. *Front Immunol* 2014; 5:442.
 44. Lotvall J, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C, Gho YS, Kurochkin IV, Mathivanan S, Quesenberry P, Sahoo S, Tahara H, Wauben MH, Witwer KW, Thery C. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J Extracell Vesicles* 2014;3:26913.
 45. Fader CM, Colombo MI. Autophagy and multivesicular bodies: two closely related partners. *Cell Death Differ* 2009;16:70–78.
 46. Buratta S, Tancini B, Sagini K, Delo F, Chiaradia E, Urbanelli L, Emiliani C. Lysosomal exocytosis, exosome release and secretory autophagy: the autophagic- and endo-lysosomal systems go extracellular. *Int J Mol Sci* 2020;21:2576.
 47. Baixauli F, Lopez-Otin C, Mittelbrunn M. Exosomes and autophagy: coordinated mechanisms for the maintenance of cellular fitness. *Front Immunol* 2014;5:403.
 48. Zhang M, Kenny SJ, Ge L, Xu K, Schekman R. Translocation of interleukin-1beta into a vesicle intermediate in autophagy-mediated secretion. *Elife* 2015;4.
 49. Nuchel J, Ghatak S, Zuk AV, Illerhaus A, Morgelin M, Schonborn K, Blumbach K, Wickstrom SA, Krieg T, Sengle G, Plomann M, Eckes B. TGFB1 is secreted through an unconventional pathway dependent on the autophagic machinery and cytoskeletal regulators. *Autophagy* 2018;14:465–486.
 50. Thoen LF, Guimaraes EL, Grunsven LA. Autophagy: a new player in hepatic stellate cell activation. *Autophagy* 2012;8:126–128.
 51. Huang TJ, Ren JJ, Zhang QQ, Kong YY, Zhang HY, Guo XH, Fan HQ, Liu LX. IGFBRP1 accelerates autophagy and activation of hepatic stellate cells via mutual regulation between H19 and PI3K/AKT/mTOR pathway. *Biomed Pharmacother* 2019;116:109034.
 52. Hernandez-Gea V, Hilscher M, Rozenfeld R, Lim MP, Nieto N, Werner S, Devi LA, Friedman SL. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. *J Hepatol* 2013; 59:98–104.
 53. Jacquin E, Leclerc-Mercier S, Judon C, Blanchard E, Fraitag S, Florey O. Pharmacological modulators of autophagy activate a parallel noncanonical pathway driving unconventional LC3 lipidation. *Autophagy* 2017; 13:854–867.
 54. Gao J, Wei B, de Assuncao TM, Liu Z, Hu X, Ibrahim S, Cooper SA, Cao S, Shah VH, Kostallari E. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis. *J Hepatol* 2020;73:1144–1154.
 55. Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernandez-Delgado I, Torralba D, Moreno-Gonzalo O, Baldanta S, Enrich C, Guerra S, Sanchez-Madrid F. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. *Nat Commun* 2016; 7:13588.
 56. Guimaraes EL, Empsen C, Geerts A, van Grunsven LA. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. *J Hepatol* 2010; 52:389–397.
 57. Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, Blaner WS. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. *J Lipid Res* 2000; 41:882–893.
 58. Martinet W, Timmermans JP, De Meyer GR. Methods to assess autophagy in situ: transmission electron microscopy versus immunohistochemistry. *Methods Enzymol* 2014;543:89–114.
 59. Szataneck R, Baran J, Siedlar M, Baj-Krzyworzeka M. Isolation of extracellular vesicles: determining the correct approach (review). *Int J Mol Med* 2015;36:11–17.
 60. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 1994; 19:1513–1520.
 61. Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. *J Clin Pathol* 2009;62:84–88.
 62. Elfimova N, Sievers E, Eischeid H, Kwiecinski M, Noetel A, Hunt H, Becker D, Frommolt P, Quasdorff M, Steffen HM, Nurnberg P, Buttner R, Teufel A, Dienes HP, Drebber U, Odenthal M. Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration. *Biochim Biophys Acta* 2013; 1833:1190–1198.

Received June 4, 2021. Accepted February 17, 2022.

Correspondence

Address correspondence to: Inge Mannaerts, PhD, Vrije Universiteit Brussel, Brussel, Belgium. e-mail: inge.mannaerts@vub.be; or Margarete Odenthal,

PhD, Institute for Pathology, University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, Germany. e-mail: m.odenthal@uni-koeln.de; fax: +49-221-478-6360.

Acknowledgments

The authors thank the German Liver Foundation and the German Competence Network for Viral Hepatitis (HepNet), initiated and coordinated by Michael Manns (Medical School Hannover, Hannover, Germany), for having the opportunity to obtain biopsy and serum specimens from the central tissue and serum bank, respectively. Furthermore, they thank Monika Kwiecinski and Hannah Eiseid-Scholz for their support in cell culture and miR-29 analysis and Melanie Ruhrländer for RNA extraction from FFPE biopsies. They thank Claudia Köhne for her support in electron microscopy and Silke Bellinghausen for the excellent technical assistance in primary HSC isolation.

CRedit Authorship Contributions

Margarete Odenthal, PhD (Conceptualization: Lead; Funding acquisition: Lead; Investigation: Lead; Project administration: Equal; Resources: Equal; Writing – original draft: Lead)

Xiaojie Yu (Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Supporting; Project administration: Supporting; Validation: Lead; Visualization: Lead; Writing – original draft: Supporting; Writing – review & editing: Supporting)

Inge Mannaerts (Investigation: Lead; Project administration: Lead; Data curation: supporting)

Natalia Elfimova (Data curation: Supporting)

Marion Mueller (Methodology: Supporting)

Daniel Bachurski (Methodology: Supporting; Data curation: supporting)

Ulrike Koitzsch (Methodology: Supporting)

Uta Drebber (Resources: Supporting)

Esther Mahabir (Resources: Supporting; Writing – review & editing: Supporting)

Hinrich P. Hansen (Methodology: Supporting)

Scott Laurence Friedman (Resources: Supporting; Writing – review & editing: Supporting)

Sabine Klein (Methodology: Supporting)

Hans Peter Dienes (Resources: Supporting)

Marianna Hoesel (Resources: Supporting; Writing – review & editing: Supporting)

Reinhard Buettner (Funding acquisition: Equal; Resources: Equal)

Jonel Trebicka (Investigation: Supporting; Methodology: Supporting; Writing – review & editing: Supporting)

Vangelis Kondylis (Resources: Supporting; Writing – review & editing: Supporting)

Conflicts of interest

The authors disclose no conflicts.

Funding

Supported by German Liver Foundation (MO), the Heinrich Hertz Foundation (MO), the Center for Molecular Medicine Cologne (CMMC) to RB, MO, and the German Research Foundation (DFG OD/6-1) to MO, (SFB TRR57/ P18) to JT, (DFG KO 5827/2-1) to VK, and (DFG HA2432/3-2) to HH. In addition, financial support was received from the Research and Education programme of the Medical Faculty of the University of Cologne and the German Competence Network for Viral Hepatitis (HepNet), funded by the German Federal Ministry of Education and Research (BMBF), Grant No 01KI0601 (HPD/MO). Jonel Trebicka is supported by the European Union's Horizon 2020 Research and Innovation Program (Galaxy, No. 668031, MICROB-PREDICT, No. 825694 and DECISION No.84794), and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875), and Cellex Foundation (PREDICT). S.L.F. is supported by NIH grant R01 DK128289 and I.M. by a FWO-V post-doctoral fellowship (12N5419 N). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.